Skip to search formSkip to main contentSkip to account menu

aclacinomycin B

Known as: 1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexapyranosyl)oxy)-, methyl ester,(1R-(1-alpha,2-beta,4-beta))-, Aclarubicin B 
An antineoplastic oligosaccharide anthracycline antibiotic isolated from the bacterium Streptomyces galilaeus. Aclacinomycin B intercalates into DNA… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryAclacinomycin A (ACM) is a new anthracycline antibiotic with a reduced cardiac toxicity in animal models. A phase II study… 
1993
1993
PURPOSE Aclacinomycin A is an oligosaccharide anthracycline that, by contrast with daunomycin, lacks carcinogenicity. The authors… 
1987
1987
Aclacinomycin A (ACLA-A), an anthracycline antibiotic, was administered in a Phase II study to 20 patients with advanced… 
1982
1982
Aclacinomycin A (ACM) is a new anthracycline antibiotic that produces substantially less cardiotoxicity in animals than does… 
1981
1981
Activities of marker enzymes for various cell components were studied with extracts of adriamycin-, aclacinomycin A- and… 
1980
1980
Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 patients with acute lymphocytic… 
1979
1979
The in vitro metabolism of the antitumor anthracycline antibiotic, aclacinomycin-A, was studied using rat liver homogenate. In… 
1979
1979
Aclacinomycin-A is a new anthracycline glycoside and has less cardiotoxicity than adriamycin. In an attempt to provide an…